JPMorgan Chase & Co. raised its stake in Spark Therapeutics, Inc. (NASDAQ:ONCE) by 3.8% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 1,607,972 shares of the biotechnology company’s stock after buying an additional 58,879 shares during the quarter. JPMorgan Chase & Co. owned approximately 5.19% of Spark Therapeutics worth $96,060,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. BNP Paribas Arbitrage SA raised its stake in shares of Spark Therapeutics by 530.1% during the second quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock valued at $174,000 after purchasing an additional 2,449 shares in the last quarter. Pacad Investment Ltd. raised its stake in shares of Spark Therapeutics by 75.0% during the second quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 1,500 shares in the last quarter. Highbridge Capital Management LLC bought a new stake in shares of Spark Therapeutics during the first quarter valued at about $227,000. KCG Holdings Inc. raised its stake in shares of Spark Therapeutics by 9.4% during the first quarter. KCG Holdings Inc. now owns 6,247 shares of the biotechnology company’s stock valued at $333,000 after purchasing an additional 538 shares in the last quarter. Finally, Legal & General Group Plc raised its stake in shares of Spark Therapeutics by 16.8% during the second quarter. Legal & General Group Plc now owns 8,931 shares of the biotechnology company’s stock valued at $532,000 after purchasing an additional 1,286 shares in the last quarter. Institutional investors own 91.01% of the company’s stock.
In other news, Director Anand Mehra sold 6,302 shares of the company’s stock in a transaction on Wednesday, June 21st. The stock was sold at an average price of $65.00, for a total transaction of $409,630.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Katherine A. High sold 10,000 shares of the company’s stock in a transaction on Monday, June 19th. The shares were sold at an average price of $60.00, for a total value of $600,000.00. Following the transaction, the insider now directly owns 220,000 shares in the company, valued at approximately $13,200,000. The disclosure for this sale can be found here. Insiders have sold 371,160 shares of company stock worth $26,468,351 in the last ninety days. 7.30% of the stock is currently owned by insiders.
ONCE has been the topic of a number of recent analyst reports. Cantor Fitzgerald set a $94.00 price objective on shares of Spark Therapeutics and gave the company a “buy” rating in a research note on Monday, July 17th. Zacks Investment Research cut shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. ValuEngine upgraded shares of Spark Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. William Blair initiated coverage on shares of Spark Therapeutics in a research note on Wednesday, June 28th. They set an “outperform” rating on the stock. Finally, Chardan Capital upgraded shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $60.00 to $100.00 in a research note on Tuesday, August 8th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $83.77.
COPYRIGHT VIOLATION WARNING: This story was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.themarketsdaily.com/2017/09/10/jpmorgan-chase-co-buys-58879-shares-of-spark-therapeutics-inc-once.html.
Spark Therapeutics, Inc. (ONCE) opened at 82.22 on Friday. The firm’s market capitalization is $2.57 billion. The company’s 50-day moving average price is $77.32 and its 200-day moving average price is $62.21. Spark Therapeutics, Inc. has a 12-month low of $35.07 and a 12-month high of $86.86.
Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.75) by $0.14. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The firm had revenue of $1.48 million for the quarter, compared to analyst estimates of $1.33 million. During the same period last year, the company earned ($1.04) EPS. The company’s revenue was up 14.7% compared to the same quarter last year. Equities analysts expect that Spark Therapeutics, Inc. will post ($7.69) EPS for the current fiscal year.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.